$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna

$dna Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000162828024008052 Filed on February 29, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$34.76M	$251.5M	$98.29M
YoY Change	-64.64%	-47.36%	-33.81%
Cost Of Revenue	$6.611M	$54.01M	$30.22M
YoY Change	-78.12%	-73.55%	-54.61%
Gross Profit	$28.14M	$197.5M	$68.07M
YoY Change	-58.65%	-27.8%	-16.91%
Gross Profit Margin	80.98%	78.52%	69.25%
Selling, General & Admin	-$30.64M	$192.9M	$93.77M
YoY Change	-132.68%	-86.06%	-88.0%
% of Gross Profit	-108.88%	97.67%	137.76%
Research & Development	$117.0M	$580.6M	$181.2M
YoY Change	-35.39%	-44.84%	-81.61%
% of Gross Profit	415.85%	294.06%	266.14%
Depreciation & Amortization	$12.84M	$54.80M	$13.95M
YoY Change	-7.98%	48.51%	74.31%
% of Gross Profit	45.61%	27.75%	20.49%
Operating Expenses	$86.39M	$1.116B	$274.9M
YoY Change	-68.58%	-58.47%	-84.44%
Operating Profit	-$58.25M	-$864.4M	-$206.9M
YoY Change	-71.84%	-60.87%	-87.72%
Interest Expense	$2.079M	$93.00K	$9.708M
YoY Change	-78.58%	-12.26%	-150.38%
% of Operating Profit
Other Income/Expense, Net	$6.648M	-$28.53M	$35.88M
YoY Change	-81.47%	-132.59%	-63.51%
Pretax Income	-$211.9M	-$892.9M	-$188.9M
YoY Change	12.16%	-57.91%	-88.23%
Income Tax	-$198.0K	-$71.00K	-$14.77M
% Of Pretax Income
Net Earnings	-$211.7M	-$892.9M	-$176.5M
YoY Change	19.91%	-57.58%	-88.97%
Net Earnings / Revenue	-609.1%	-355.08%	-179.62%
Basic Earnings Per Share		-$0.46
Diluted Earnings Per Share	-$0.11	-$0.46	-$0.10
COMMON SHARES
Basic Shares Outstanding		1.944B shares
Diluted Shares Outstanding		1.944B shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$944.1M	$944.1M	$1.316B
YoY Change	-28.25%	-28.25%	-15.11%
Cash & Equivalents	$944.1M	$944.1M	$1.316B
Short-Term Investments
Other Short-Term Assets	$362.0K	$25.89M	$487.0K
YoY Change	-25.67%	-43.59%	-30.23%
Inventory	$46.00K	$46.00K	$4.364M
Prepaid Expenses	$10.36M		$18.15M
Receivables	$17.16M	$17.90M	$80.91M
Other Receivables	$13.84M	$13.84M	$1.561M
Total Short-Term Assets	$1.002B	$1.002B	$1.450B
YoY Change	-30.92%	-30.92%	-15.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$188.2M	$397.2M	$314.8M
YoY Change	-40.21%	-44.49%	115.94%
Goodwill	$49.24M		$60.21M
YoY Change	-18.22%		182.52%
Intangibles	$82.74M		$111.0M
YoY Change	-25.49%		413.08%
Long-Term Investments	$0.00	$78.57M	$1.543M
YoY Change	-100.0%	-30.92%	-88.31%
Other Assets	$58.06M	$42.22M	$88.73M
YoY Change	-34.57%	-52.41%	101.69%
Total Long-Term Assets	$663.6M	$663.6M	$1.089B
YoY Change	-39.08%	-39.08%	213.05%
TOTAL ASSETS
Total Short-Term Assets	$1.002B	$1.002B	$1.450B
Total Long-Term Assets	$663.6M	$663.6M	$1.089B
Total Assets	$1.665B	$1.665B	$2.539B
YoY Change	-34.42%	-34.42%	22.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.323M	$9.323M	$10.45M
YoY Change	-10.79%	-10.79%	27.62%
Accrued Expenses	$110.1M	$110.1M	$114.7M
YoY Change	-4.05%	-4.05%	22.89%
Deferred Revenue	$44.49M		$47.82M
YoY Change	-6.97%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$163.9M	$163.9M	$173.0M
YoY Change	-5.26%	-5.26%	28.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$18.73M	$404.3M	$31.19M
YoY Change	-39.94%	-35.83%	-13.34%
Total Long-Term Liabilities	$18.73M	$404.3M	$31.19M
YoY Change	-39.94%	-35.83%	-13.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$163.9M	$163.9M	$173.0M
Total Long-Term Liabilities	$18.73M	$404.3M	$31.19M
Total Liabilities	$568.2M	$568.2M	$803.0M
YoY Change	-29.25%	-29.25%	59.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$5.291B		-$4.398B
YoY Change	20.3%		91.38%
Common Stock	$199.0K		$190.0K
YoY Change	4.74%		18.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.097B	$1.097B	$1.736B
YoY Change
Total Liabilities & Shareholders Equity	$1.665B	$1.665B	$2.539B
YoY Change	-34.42%	-34.42%	22.61%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$211.7M	-$892.9M	-$176.5M
YoY Change	19.91%	-57.58%	-88.97%
Depreciation, Depletion And Amortization	$12.84M	$54.80M	$13.95M
YoY Change	-7.98%	48.51%	74.31%
Cash From Operating Activities	-$57.83M	-$295.5M	-$104.7M
YoY Change	-44.77%	17.17%	-36.75%
INVESTING ACTIVITIES
Capital Expenditures	$3.446M	$40.80M	$25.65M
YoY Change	-86.56%	-21.94%	-601.47%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	-$43.23M	$990.0K	$55.39M
YoY Change	-178.05%	125.51%	492.86%
Cash From Investing Activities	-$46.67M	-$80.69M	$29.74M
YoY Change	-256.94%	19.73%	603.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-632.0K	-$3.216M	97.93M
YoY Change	-100.65%	-103.37%	-986.83%
NET CHANGE
Cash From Operating Activities	-57.83M	-$295.5M	-104.7M
Cash From Investing Activities	-46.67M	-$80.69M	29.74M
Cash From Financing Activities	-632.0K	-$3.216M	97.93M
Net Change In Cash	-105.1M	-$380.0M	22.97M
YoY Change	-557.67%	70.14%	-113.33%
FREE CASH FLOW
Cash From Operating Activities	-$57.83M	-$295.5M	-$104.7M
Capital Expenditures	$3.446M	$40.80M	$25.65M
Free Cash Flow	-$61.28M	-$336.3M	-$130.3M
YoY Change	-52.99%	10.45%	-18.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1052643000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1149662000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	862952000	usd
CY2022	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	2142304000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	252000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	981000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001830214
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2433000000	usd
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	944073000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1315792000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17157000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	80907000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	742000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1558000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39777000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51822000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1001749000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1450079000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188193000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	314773000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	206801000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400762000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	78565000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni And Without Readily Determinable Fair Value EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue	112188000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1543000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	82741000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	111041000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	49238000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	60210000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	58055000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	88725000	usd
CY2023Q4	us-gaap	Assets Assets	1665342000	usd
CY2022Q4	us-gaap	Assets Assets	2539321000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9323000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10451000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	44486000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	47817000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	110051000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	114694000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163860000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	172962000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	158062000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	174767000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	221835000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	413256000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	5700000	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	10868000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18733000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	31191000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	568190000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	803044000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	199000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	190000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6385997000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6136378000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-5290528000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4397659000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1484000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2632000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1097152000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1736277000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1665342000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2539321000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	251455000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	477706000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	313837000	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	96210000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	1115861000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2686658000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-864406000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2208952000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1828467000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	57217000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	20262000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	837000	usd
CY2023	us-gaap	Interest Expense InterestExpense	93000	usd
CY2022	us-gaap	Interest Expense InterestExpense	106000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2373000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2635000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43761000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-54827000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-53335000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5168000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-124970000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58615000	usd
CY2023	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	0	usd
CY2022	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	0	usd
CY2021	dna	Gain On Settlement Of Partnership Agreement GainOnSettlementOfPartnershipAgreement	23826000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-42502000	usd
CY2023	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	9138000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28534000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	87553000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-892940000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2121399000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1838122000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-71000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15027000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1480000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-892869000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2106372000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1443000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6595000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1944420000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1679061000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1944420000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1679839000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360373000	shares
CY2022	us-gaap	Profit Loss ProfitLoss	-2106372000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4116000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-917000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1715000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4116000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-917000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1715000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-888753000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2107289000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1838357000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	470052000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	176000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9463000	usd
CY2021	dna	Founder Shares Repurchase Value FounderSharesRepurchaseValue	24998000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	300000	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15160000	usd
CY2021	dna	Issuance Of Common Stock Upon Reverse Recapitalization Net Of Offering Costs Value IssuanceOfCommonStockUponReverseRecapitalizationNetOfOfferingCostsValue	1509629000	usd
CY2021	dna	Assumption Of Public And Private Placement Warrants AssumptionOfPublicAndPrivatePlacementWarrants	194453000	usd
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	59933000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1579400000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1715000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1567379000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	279745000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	98910000	usd
CY2022	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	55408000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1947474000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-917000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2106372000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1736277000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	555000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	23000	usd
CY2023	dna	Issuance Of Common Stock Upon Exercise Of Public Warrants Amount IssuanceOfCommonStockUponExerciseOfPublicWarrantsAmount	-8896000	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	6820000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2500000	usd
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	56000	shares
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	230880000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	4116000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-892869000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1097152000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-892869000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2106372000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-1836642000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	70507000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42552000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	29076000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	229884000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1930641000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1606020000	usd
CY2023	dna	Noncash Customer Consideration NoncashCustomerConsideration	-1373000	usd
CY2022	dna	Noncash Customer Consideration NoncashCustomerConsideration	-34263000	usd
CY2021	dna	Noncash Customer Consideration NoncashCustomerConsideration	-24185000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2635000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43761000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-54827000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-53335000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000	usd
CY2023	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	2416000	usd
CY2022	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	-3757000	usd
CY2021	dna	Changes In Fair Value Of Loans Receivable ChangesInFairValueOfLoansReceivable	3508000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5168000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-124970000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-58615000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-9168000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	1262000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	293000	usd
CY2023	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	-42502000	usd
CY2022	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	31889000	usd
CY2021	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	usd
CY2023	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	-121404000	usd
CY2022	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	usd
CY2021	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-801000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14609000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-842000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3091000	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	28313000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	19082000	usd
CY2023	dna	Noncash In Process Research And Development NoncashInProcessResearchAndDevelopment	9182000	usd
CY2022	dna	Noncash In Process Research And Development NoncashInProcessResearchAndDevelopment	1162000	usd
CY2021	dna	Noncash In Process Research And Development NoncashInProcessResearchAndDevelopment	0	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1047000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1871000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	usd
CY2023	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	0	usd
CY2022	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	6152000	usd
CY2021	us-gaap	Amortization Of Acquisition Costs AmortizationOfAcquisitionCosts	0	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2147000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-283000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-50068000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-55024000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	114094000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-10473000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8523000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3607000	usd
CY2023	dna	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	-9275000	usd
CY2022	dna	Increase Decrease Right Of Use Assets IncreaseDecreaseRightOfUseAssets	-13233000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2570000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-921000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	539000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1183000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10844000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2247000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	16899000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-39639000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	44796000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-35917000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-36417000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10498000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22800000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-10792000	usd
CY2021	us-gaap	Straight Line Rent StraightLineRent	-6032000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	452000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	31000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18620000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-295500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-252198000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-253818000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	40801000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52271000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56521000	usd
CY2023	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	42980000	usd
CY2022	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	55721000	usd
CY2021	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	0	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-82367000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	12040000	usd
CY2023	dna	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2022	dna	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	7639000	usd
CY2021	dna	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2023	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	350000	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	40000000	usd
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
CY2023	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	10000000	usd
CY2021	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	304000	usd
CY2023	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	3691000	usd
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	5000000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4428000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	990000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	439000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80693000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67394000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73257000	usd
CY2023	dna	Recapitalization Redemption Amounts RecapitalizationRedemptionAmounts	867253000	usd
CY2023	dna	Recapitalization Offering Costs RecapitalizationOfferingCosts	108118000	usd
CY2023	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts	0	usd
CY2022	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts	0	usd
CY2021	dna	Proceeds From Reverse Recapitalization Net Of Redemption And Offering Costs ProceedsFromReverseRecapitalizationNetOfRedemptionAndOfferingCosts	1509629000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	93000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	240000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	167000	usd
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	usd
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	24998000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	23000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	981000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9463000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1295000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1237000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1123000	usd
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	59933000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	99303000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1411000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	521000	usd
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	580000	usd
CY2022	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1467000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3216000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	95337000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-588000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	908000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-379997000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-223347000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1315792000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1550004000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	53789000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	42924000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1369581000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1592928000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	944073000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1315792000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	45511000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	53789000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	989584000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1369581000	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. In the accompanying consolidated balance sheet, $4.4 million in inventory as of December 31, 2022 was reclassified from inventory, net to prepaid expenses and other current assets. Total current assets as of December 31, 2022 is not changed as a result of this reclassification. In the accompanying consolidated statements of cash flows, (i) $0.2 million and $0.6 million of changes in inventory were reclassified to changes in prepaid expenses and other current assets for the years ended December 31, 2022 and 2021, respectively, (ii) $1.3 million and $0.3 million was reclassified from other non-cash activity to change in fair value of contingent consideration liability for the years ended December 31, 2022 and 2021, respectively, and (iii) $1.2 million was reclassified from other non-cash activity to non-cash in-process research and development for the year ended December 31, 2022. The total cash used in operating activities for the years ended December 31, 2022 and 2021 is not changed as a result of these reclassifications.</span></div>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1000000.0	usd
CY2021	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	dna	Accrued Interest And Penalties AccruedInterestAndPenalties	0	usd
CY2022Q4	dna	Accrued Interest And Penalties AccruedInterestAndPenalties	0	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	11100000	usd
CY2022	dna	Retention Amount RetentionAmount	7400000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	4700000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P15Y
CY2021Q3	dna	Shares Exchange Ratio SharesExchangeRatio	49.080452
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Share Price SharePrice	12.50
CY2021Q4	dna	Earnout Shares Vested And Outstanding EarnoutSharesVestedAndOutstanding	38800000	shares
CY2021Q3	dna	Other Offering Costs OtherOfferingCosts	-108118000	usd
CY2021Q3	dna	Net Proceeds From Business Acquisition NetProceedsFromBusinessAcquisition	1509629000	usd
CY2023Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	13601000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	959467000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	18468000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	5805000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	29973000	usd
CY2022Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	37660000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1154337000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6378000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	18095000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	35341000	usd
CY2022Q4	dna	Financing Receivable Purchased Amount At Purchase Price FinancingReceivablePurchasedAmountAtPurchasePrice	30000000	usd
CY2023Q4	dna	Financing Receivable Purchased Amount At Purchase Price FinancingReceivablePurchasedAmountAtPurchasePrice	30000000	usd
CY2023Q4	dna	Number Of Convertible Promissory Notes NumberOfConvertiblePromissoryNotes	2	promissorynote
CY2023Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10300000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	7660000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	11559000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	2653000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases	7660000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues	13939000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues	0	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	10404000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	7707000	usd
CY2023	dna	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	Change in fair value
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-2416000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	705000	usd
CY2023	dna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Write Off FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetWriteOff	0	usd
CY2022	dna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Write Off FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetWriteOff	1860000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	14129000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	7660000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-1808000	usd
CY2023Q4	us-gaap	Investments Investments	78565000	usd
CY2022Q4	us-gaap	Investments Investments	112188000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2022Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1543000	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-54827000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2635000	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43761000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77284000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	44043000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	10310000	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	9157000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	43025000	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	11543000	usd
CY2023	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	1627000	usd
CY2022	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	0	usd
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount	0	usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	-54827000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-53335000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-11543000	usd
CY2022	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	1
CY2022	dna	Number Of Ventures Formed NumberOfVenturesFormed	2	acquisition
CY2022Q4	us-gaap	Goodwill Goodwill	60210000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	21312000	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	39712000	usd
CY2023	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	-10660000	usd
CY2022	us-gaap	Goodwill Other Increase Decrease GoodwillOtherIncreaseDecrease	0	usd
CY2023	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-2120000	usd
CY2022	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	-548000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	266000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	49238000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	60210000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	105849000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23108000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	82741000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	120094000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9053000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	111041000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15700000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5600000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	13747000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	13623000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13623000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10548000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3442000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	27758000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	82741000	usd
CY2023Q3	dna	Lessee Operating Lease Area Of Real Estate Property LesseeOperatingLeaseAreaOfRealEstateProperty	300000	sqft
CY2023Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	96200000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.085
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	59588000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	35242000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1047000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1871000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	79000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	104000	usd
CY2023	dna	Finance Lease Cost FinanceLeaseCost	1126000	usd
CY2022	dna	Finance Lease Cost FinanceLeaseCost	1975000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	15862000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	8879000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	11170000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	5190000	usd
CY2023	us-gaap	Lease Cost LeaseCost	65406000	usd
CY2022	us-gaap	Lease Cost LeaseCost	40906000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	17700000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	44051000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	13587000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	83000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	92000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1295000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1237000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y3M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.071
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.037
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.037
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	43566000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1082000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	45216000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	455000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	39400000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	20000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	39356000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	40592000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	222910000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	431040000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1557000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	190327000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	21000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	240713000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1536000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18878000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1055000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	221835000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	481000	usd
CY2023Q4	dna	Lessee Operating Lease Lease Not Yet Commenced Undiscounted Amount LesseeOperatingLeaseLeaseNotYetCommencedUndiscountedAmount	396500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1 LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1	P15Y
CY2023	dna	Termof Sublease TermofSublease	P5Y
CY2021Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q1	dna	Number Of Trading Days To Determine Call Of Warrant Redemption NumberOfTradingDaysToDetermineCallOfWarrantRedemption	P30D
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	944073000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1315792000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1550004000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4789000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8221000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	40722000	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	45568000	usd
CY2021Q4	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	42924000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	989584000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1369581000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1592928000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	12293000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10360000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18145000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	10063000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	16960000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4789000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	8221000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	1546000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	1561000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	318000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	2084000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	46000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	4364000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	362000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	487000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	39777000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51822000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	308911000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	407529000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	120718000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	92756000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	188193000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	314773000	usd
CY2023	us-gaap	Depreciation Depreciation	54800000	usd
CY2022	us-gaap	Depreciation Depreciation	36900000	usd
CY2021	us-gaap	Depreciation Depreciation	26900000	usd
CY2023	dna	Tangible Asset Impairment Number Of Facilities With Impaired Equipment TangibleAssetImpairmentNumberOfFacilitiesWithImpairedEquipment	2	facility
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	40722000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	45568000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	13601000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	37660000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2230000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3256000	usd
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	1502000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	2241000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	58055000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	88725000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	27884000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	12178000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	18878000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28032000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	18468000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	6378000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15678000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19441000	usd
CY2023Q4	us-gaap	Deferred Income DeferredIncome	4009000	usd
CY2022Q4	us-gaap	Deferred Income DeferredIncome	0	usd
CY2023Q4	dna	Accrued Biosecurity Service Revenue Accruals Current AccruedBiosecurityServiceRevenueAccrualsCurrent	3564000	usd
CY2022Q4	dna	Accrued Biosecurity Service Revenue Accruals Current AccruedBiosecurityServiceRevenueAccrualsCurrent	15401000	usd
CY2023Q4	dna	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	2739000	usd
CY2022Q4	dna	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	1844000	usd
CY2023Q4	dna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	2667000	usd
CY2022Q4	dna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	11624000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1055000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1300000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	861000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3434000	usd
CY2023Q4	dna	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	14248000	usd
CY2022Q4	dna	Accrued Lab Supplies Current AccruedLabSuppliesCurrent	15062000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	110051000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	114694000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	83000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	92000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2370000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	670000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	61000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	27668000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	79984000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	1729000	usd
CY2023	dna	Purchase Of Minority Interest PurchaseOfMinorityInterest	0	usd
CY2022	dna	Purchase Of Minority Interest PurchaseOfMinorityInterest	7390000	usd
CY2021	dna	Purchase Of Minority Interest PurchaseOfMinorityInterest	0	usd
CY2023	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases	0	usd
CY2022	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases	0	usd
CY2021	dna	Purchases Of Equipment Through Capital Leases PurchasesOfEquipmentThroughCapitalLeases	1981000	usd
CY2021	dna	Lease Financing Obligation For Build To Suit Lease LeaseFinancingObligationForBuildToSuitLease	6120000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2915000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12881000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1815000	usd
CY2023	dna	Equity Received In Related Parties EquityReceivedInRelatedParties	0	usd
CY2022	dna	Equity Received In Related Parties EquityReceivedInRelatedParties	8873000	usd
CY2021	dna	Equity Received In Related Parties EquityReceivedInRelatedParties	61554000	usd
CY2023	dna	Convertible Financial Instruments Received For Foundry Services ConvertibleFinancialInstrumentsReceivedForFoundryServices	4542000	usd
CY2022	dna	Convertible Financial Instruments Received For Foundry Services ConvertibleFinancialInstrumentsReceivedForFoundryServices	29074000	usd
CY2021	dna	Convertible Financial Instruments Received For Foundry Services ConvertibleFinancialInstrumentsReceivedForFoundryServices	0	usd
CY2023	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities	17450000	usd
CY2022	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities	3423000	usd
CY2021	dna	Purchase Of Non Cash Marketable Equity Securities PurchaseOfNonCashMarketableEquitySecurities	10000000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	195000	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	0	usd
CY2022	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	231750000	usd
CY2021	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	0	usd
CY2023	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	6820000	usd
CY2022	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	40382000	usd
CY2021	us-gaap	Interest Income Securities Us Treasury And Other Us Government InterestIncomeSecuritiesUSTreasuryAndOtherUSGovernment	15087000	usd
CY2023	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	0	usd
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	19912000	usd
CY2021	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	8760000	usd
CY2023	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities	0	usd
CY2022	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities	0	usd
CY2021	dna	Initial Fair Value Of Warrant Liabilities InitialFairValueOfWarrantLiabilities	194453000	usd
CY2023	dna	Settlement Of Contingent Consideration SettlementOfContingentConsideration	8896000	usd
CY2022	dna	Settlement Of Contingent Consideration SettlementOfContingentConsideration	0	usd
CY2021	dna	Settlement Of Contingent Consideration SettlementOfContingentConsideration	0	usd
CY2023	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses	0	usd
CY2022	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses	578000	usd
CY2021	dna	Series E Convertible Preferred Stock Issuance Costs Included In Accrued Expenses SeriesEConvertiblePreferredStockIssuanceCostsIncludedInAccruedExpenses	0	usd
CY2023Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Term UnrecordedUnconditionalPurchaseObligationTerm	P5Y
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	8000000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	28000000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary	54000000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary	86000000	usd
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fifth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary	113000000	usd
CY2023	dna	Revenue Remaining Performance Obligations Number Of Milestones RevenueRemainingPerformanceObligationsNumberOfMilestones	2	milestone
CY2023Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	286100000	usd
CY2022Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Term UnrecordedUnconditionalPurchaseObligationTerm	P4Y
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	58000000	usd
CY2022Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Term UnrecordedUnconditionalPurchaseObligationTerm	P4Y
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	10000000	usd
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	13000000	usd
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary	16000000	usd
CY2023Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary	19000000	usd
CY2021Q3	dna	Number Of Demands Per Calendar Year NumberOfDemandsPerCalendarYear	2	demand
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2138993000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2001315000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2031884000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1891976000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	15800000000	shares
CY2023	us-gaap	Dividends Dividends	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	152168000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	423534000	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	229884000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1930641000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1682565000	usd
CY2023Q4	dna	Share Based Compensation Arrangement Common Stock Reserved For Issuance Increase Term ShareBasedCompensationArrangementCommonStockReservedForIssuanceIncreaseTerm	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10501000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.34
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	979000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.90
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	5431000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.02
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6049000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.89
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6810000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4928000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.60
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P1Y10M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6810000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1700000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	9100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	21500000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	91000000.0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.43
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.97
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0394
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0313
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0011
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.930
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.769
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.886
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M6D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y11M15D
CY2021Q3	dna	Business Combination Number Of Tranches BusinessCombinationNumberOfTranches	4	tranche
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	65900000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	222600000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	45600000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	189200000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	110000000.0	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	123500000	usd
CY2023	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	2300000	usd
CY2022	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	10000000	usd
CY2021	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	6400000	usd
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	dna	Number Of Core Assets NumberOfCoreAssets	2	asset
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	251455000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	477706000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	313837000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-864406000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2208952000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-1828467000	usd
CY2023	dna	Employer Payroll Taxes EmployerPayrollTaxes	5000000.0	usd
CY2022	dna	Employer Payroll Taxes EmployerPayrollTaxes	10300000	usd
CY2021	dna	Employer Payroll Taxes EmployerPayrollTaxes	5000000.0	usd
CY2021	dna	Number Of Allocated Performance Obligations NumberOfAllocatedPerformanceObligations	10	obligation
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Five RevenueRemainingPerformanceObligationAmountFive	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Eight RevenueRemainingPerformanceObligationAmountEight	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Three RevenueRemainingPerformanceObligationAmountThree	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Four RevenueRemainingPerformanceObligationAmountFour	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Two RevenueRemainingPerformanceObligationAmountTwo	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Seven RevenueRemainingPerformanceObligationAmountSeven	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Ten RevenueRemainingPerformanceObligationAmountTen	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Six RevenueRemainingPerformanceObligationAmountSix	3600000	usd
CY2021Q4	dna	Revenue Remaining Performance Obligation Amount Nine RevenueRemainingPerformanceObligationAmountNine	3600000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-15457000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1481000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-71000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15027000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1480000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	8200000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	6100000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3700000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-890986000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2118095000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1837497000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1954000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3304000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-625000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-892940000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-2121399000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1838122000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	690000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	271000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	123000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	159000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	813000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	430000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10500000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-413000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3943000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-912000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-884000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1014000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-156000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-884000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.136
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.239
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.142
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.167
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.002
CY2023	dna	Executive Compensation ExecutiveCompensation	-0.081
CY2022	dna	Executive Compensation ExecutiveCompensation	0.053
CY2021	dna	Executive Compensation ExecutiveCompensation	0.020
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.006
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.009
CY2023	dna	Effective Income Tax Rate Reconciliation Investments In Subsidiaries And Other Percent EffectiveIncomeTaxRateReconciliationInvestmentsInSubsidiariesAndOtherPercent	-0.290
CY2022	dna	Effective Income Tax Rate Reconciliation Investments In Subsidiaries And Other Percent EffectiveIncomeTaxRateReconciliationInvestmentsInSubsidiariesAndOtherPercent	0
CY2021	dna	Effective Income Tax Rate Reconciliation Investments In Subsidiaries And Other Percent EffectiveIncomeTaxRateReconciliationInvestmentsInSubsidiariesAndOtherPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.016
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.007
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	277559000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	434020000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	174127000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	64157000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	74336000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	37455000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	185462000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	162601000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	616000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1330000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2690000	usd
CY2023Q4	dna	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	36225000	usd
CY2022Q4	dna	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	46798000	usd
CY2021Q4	dna	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	45928000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	83037000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	124126000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	318049000	usd
CY2023Q4	dna	Deferred Tax Assets Amortizable Intangibles DeferredTaxAssetsAmortizableIntangibles	5505000	usd
CY2022Q4	dna	Deferred Tax Assets Amortizable Intangibles DeferredTaxAssetsAmortizableIntangibles	6010000	usd
CY2021Q4	dna	Deferred Tax Assets Amortizable Intangibles DeferredTaxAssetsAmortizableIntangibles	3834000	usd
CY2023Q4	dna	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	60197000	usd
CY2022Q4	dna	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	113665000	usd
CY2021Q4	dna	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	0	usd
CY2023Q4	dna	Deferred Tax Assets Investments In Subsidiaries DeferredTaxAssetsInvestmentsInSubsidiaries	58447000	usd
CY2022Q4	dna	Deferred Tax Assets Investments In Subsidiaries DeferredTaxAssetsInvestmentsInSubsidiaries	0	usd
CY2021Q4	dna	Deferred Tax Assets Investments In Subsidiaries DeferredTaxAssetsInvestmentsInSubsidiaries	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2927000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	952000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	863000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	772157000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	963749000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	585010000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	711778000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	833086000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	583107000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	60379000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	130663000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1903000	usd
CY2023Q4	dna	Deferred Tax Liabilities Amortizable Intangibles DeferredTaxLiabilitiesAmortizableIntangibles	16873000	usd
CY2022Q4	dna	Deferred Tax Liabilities Amortizable Intangibles DeferredTaxLiabilitiesAmortizableIntangibles	23583000	usd
CY2021Q4	dna	Deferred Tax Liabilities Amortizable Intangibles DeferredTaxLiabilitiesAmortizableIntangibles	4722000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	410000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13405000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	830000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	52409000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	103357000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	usd
CY2023Q4	dna	Deferred Tax Liabilities Basis Differences DeferredTaxLiabilitiesBasisDifferences	0	usd
CY2022Q4	dna	Deferred Tax Liabilities Basis Differences DeferredTaxLiabilitiesBasisDifferences	0	usd
CY2021Q4	dna	Deferred Tax Liabilities Basis Differences DeferredTaxLiabilitiesBasisDifferences	1522000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	69692000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	140345000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7074000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9313000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9682000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5171000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	833086000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-121308000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	711778000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	583107000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	249979000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	833086000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-121300000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-892869000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-2104929000	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-1830047000	usd
CY2023	dna	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	0	usd
CY2022	dna	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	0	usd
CY2021	dna	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	58615000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3143000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2023	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-892869000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-2108072000	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-1888662000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1944420000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1679061000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1359849000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	525000	shares
CY2023	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	777000	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Contingently Issuable Shares IncrementalCommonSharesAttributableToContingentlyIssuableShares	0	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1944420000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1679839000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1360373000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.39
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	363803000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	355757000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	354729000	shares

Files In Submission

Name	View Source	Status
MetaLinks.json	Edgar Link	pending
0001628280-24-008052-index-headers.html	Edgar Link	pending
0001628280-24-008052-index.html	Edgar Link	pending
0001628280-24-008052.txt	Edgar Link	pending
0001628280-24-008052-xbrl.zip	Edgar Link	pending
dna-20231231.htm	Edgar Link	pending
dna-20231231.xsd	Edgar Link	pending
dna-20231231xex1031.htm	Edgar Link	pending
dna-20231231xex211.htm	Edgar Link	pending
dna-20231231xex231.htm	Edgar Link	pending
dna-20231231xex311.htm	Edgar Link	pending
dna-20231231xex312.htm	Edgar Link	pending
dna-20231231xex321.htm	Edgar Link	pending
dna-20231231xex322.htm	Edgar Link	pending
dna-20231231xex42.htm	Edgar Link	pending
dna-20231231xex97.htm	Edgar Link	pending
dna-20231231_g1.jpg	Edgar Link	pending
dna-20231231_g10.jpg	Edgar Link	pending
dna-20231231_g11.jpg	Edgar Link	pending
dna-20231231_g12.jpg	Edgar Link	pending
dna-20231231_g2.jpg	Edgar Link	pending
dna-20231231_g3.jpg	Edgar Link	pending
dna-20231231_g4.jpg	Edgar Link	pending
dna-20231231_g5.jpg	Edgar Link	pending
dna-20231231_g6.jpg	Edgar Link	pending
dna-20231231_g7.jpg	Edgar Link	pending
dna-20231231_g8.jpg	Edgar Link	pending
dna-20231231_g9.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
dna-20231231_cal.xml	Edgar Link	unprocessable
dna-20231231_def.xml	Edgar Link	unprocessable
dna-20231231_lab.xml	Edgar Link	unprocessable
dna-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dna-20231231_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna

2023 Q4 Form 10-K Financial Statement

#000162828024008052 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNA Ginkgo Bioworks Holdings, Inc. Stock $dna

2023 Q4 Form 10-K Financial Statement

#000162828024008052 Filed on February 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNA
Ginkgo Bioworks Holdings, Inc. Stock $dna